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Abstract: One of the limitations of cancer research has been the restricted focus on tumor cells and
the omission of other non-malignant cells that are constitutive elements of this systemic disease.
Current research is focused on the bidirectional communication between tumor cells and other
components of the tumor microenvironment (TME), such as immune and endothelial cells, and nerves.
A major success of this bidirectional approach has been the development of immunotherapy. Recently,
a more complex landscape involving a multi-lateral communication between the non-malignant
components of the TME started to emerge. A prime example is the interplay between immune
and endothelial cells, which led to the approval of anti-vascular endothelial growth factor-therapy
combined with immune checkpoint inhibitors and classical chemotherapy in non-small cell lung cancer.
Hence, a paradigm shift approach is to characterize the crosstalk between different non-malignant
components of the TME and understand their role in tumorigenesis. In this perspective, we discuss
the interplay between nerves and immune cells within the TME. In particular, we focus on exosomes
and microRNAs as a systemic, rapid and dynamic communication channel between tumor cells,
nerves and immune cells contributing to cancer progression. Finally, we discuss how combinatorial
therapies blocking this tumorigenic cross-talk could lead to improved outcomes for cancer patients.
Keywords: tumor microenvironment; immune system; neurotropic carcinoma; neurogenesis;
exosomes; microRNAs
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1. Introduction
1.1. A New Perspective on the Tumor Microenvironment
Cancer is a devastating disease that has become the leading cause of death in developed
countries [1], despite enormous efforts to decipher the key molecular events responsible for its onset
and progression. All solid tumors are composed of cancer cells embedded between several types
of non-malignant specialized cells which are essential to tumorigenesis and comprise the tumor
microenvironment (TME) [2]. The TME is a unique environment emerging during tumor progression
as a result of the interactions between tumor cells and the host. It is created, continuously modified and
dominated by the tumor, which orchestrates molecular and cellular events taking place in surrounding
tissues [3]. Apart from cancer cells, the TME is a complex mixture of endothelial cells (responsible for
neo-angiogenesis), pericytes, immune cells (responsible for immune distraction and tumor promoting
inflammation), fibroblasts, undifferentiated progenitor cells [2] and, according to more recent studies,
nerves [4]. Current research focuses mainly on the bidirectional communication between tumor
cells and the other components of the TME. An important success of this bidirectional approach
was the development of immunotherapy, especially of the monoclonal antibodies against cytotoxic
T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD1)/ programmed
death-ligand 1 (PD-L1). Unfortunately, only a minority of cancer patients attain complete response
to immunotherapy [5], thus novel therapeutic strategies must be developed. A growing body of
evidence suggest that elements of the TME can directly influence each other, an example being the
interplay between immune and endothelial cells. Innate immunity cells can alter vascular endothelial
growth factor (VEGF) receptor expression [6,7]. This led to the association of anti-VEGF-A therapy
with immune checkpoint inhibitors and classical chemotherapy in non-small cell lung cancer (NSCLC).
Very interestingly, this combination led to prolonged overall survival (OS) of treatment-naive stage
IV NSCLC patients [8]. It may be speculated that the three drugs do not act separately, but together:
the cytotoxic activity of the chemotherapy combined with the vascular permeabilization induced by
the anti-VEGF-A provoke an important release of tumor antigens, hence aiding the immune checkpoint
therapy [6]. This example underscores a completely new approach to cancer treatment based on the
disruption of the cross-talk between the different non-malignant components of the TME. Along similar
lines, recent evidence suggests that there is an interplay between nerves and immune cells within the
TME [9]. We consider that understanding this relationship could lead to new combinatorial therapies
that might improve cancer outcomes. Of note, both immune cells and neurons are spread throughout
the body and can communicate in areas distant from the tumor. Therefore, the communication
mechanism must be systemic, and dynamic.
Quail and Joyce reported many examples of heterotypic signaling within the elements of TME
which involved classical paracrine signaling loops of cytokines or growth factors and their receptors [10].
Together with these key mechanisms of intercellular communication within the TME, extracellular
vesicles (EVs) have emerged as an additional way of cell–cell communication [11]. In many types of
solid tumor, cancer-derived exosomes from the primary tumor “prepare” the microenvironment to
form a pro-tumorigenic niche, and direct bone marrow-derived progenitors to enhance and promote
metastatic dissemination [12]. For example, exosomes derived from aggressive melanoma cells
increased growth and metastasis of primary tumors, and programmed bone marrow-derived cells
at the pre-metastatic site to acquire a pro-angiogenic phenotype. Interestingly, the mechanism was
due to the transport via exosomes of the receptor tyrosine kinase MET Proto-Oncogene (MET) that,
if inhibited, impaired pro-metastatic effects [13]. Hence, we allege that exosomes and their cargo might
contribute to this complex interplay.
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1.2. Exosomes and microRNAs Represent a Systemic, and Dynamic Communication Channel between the
Components of the Tumor Microenvironment
Traditionally, intercellular communication was thought to be mediated through direct cell–cell
contact or via transfer of secreted chemical messenger or macromolecules such as hormones [14].
In the last two decades, a third mechanism for intercellular communication has emerged that involves
intercellular transfer of EVs [15]. There are various types of secreted EVs that have distinct structural
and biochemical properties depending on their intracellular site of origin; however, they are still poorly
characterized and there is lack of a consensus in the nomenclature [16]. Exosomes, a specific subtype
of EVs, play a significant role in intercellular communication by serving as a carrier for the transfer of
membrane and cytosolic proteins, lipids, and RNA between cells. They arise intracellularly via inward
budding of the cell membrane of the endosomes and are released upon exocytosis of multivesicular
bodies [17,18]. Exosomes have a spherical structure, limited by a lipid bilayer, a 40–100 nm size in
diameter, and a cup-shaped appearance by electron microscopy. Exosomes display specific protein
markers such as tetraspanins (CD63, CD9), heat shock proteins (HSP70 and HSP90) as well as a wide
range of other proteins which dictate the cell types they target [19].
Each cell type is able to turn on exosomes’ biogenesis depending on the physiological state and
further control the sorting of exosomal cargo [20]. The secretion of exosomes can be spontaneous or
induced depending on the cell type and environmental changes, such as hypoxia. T cells, mastocytes,
and resting B cells secrete detectable levels of exosomes into the blood following the activation of
specific cell surface receptors [21]. By contrast, most tumor cell lines and other immune cells, such as
dendritic cells (DC) and macrophages, constitutively secrete exosomes in vitro [21]. In addition,
tumor cells release exosomes at a greater rate than normal cells [21].
Exosomes and other EVs represent the way donor cells communicate with recipient cells
and influence their gene expression [22]. Exosomes have antigen-dependent immune functions,
as they carry antigenic material and peptide–major histocompatibility complex (MHC) but also
antigen independent immune functions. RNA sequencing and proteome analyses of exosomes
revealed that these vesiclescarry both proteins and RNA molecules, including messenger RNAs
(mRNA), and non-coding RNAs (ncRNAs), such as microRNAs (miRNAs) and long non-coding RNAs
(lncRNAs) [23–25], which are transferred to recipient cells [26]. As exosomes enter their target cells
and release their cargo, they modulate cell functions and even prompt identity switching [26]. The first
to describe the cell–cell communication mediated by RNAs included in exosomes was Valadi et al.
in 2007: exosomes carried miRNAs and other RNAs from one cell to another and, when released in the
target cell, were able to interact with the gene expression machinery to modify the gene expression
profile of the recipient cell [27].
The role of miRNAs as mediators for intercellular communication with a hormone-like
mechanism has also recently been described [23,28]. Tumor-derived exosomes containing miRNAs
can in fact directly modify tumor cell invasiveness and motility through modification of the
TME [29,30]. Interestingly, the ectopic expression of miR-409 in normal prostate fibroblasts conferred
a cancer-associated stroma-like phenotype and the release of this miRNA via exosomes was able
to promote tumorigenesis and epithelial-mesenchymal transition (EMT) through repression of Ras
suppressor 1 (RUS1) and stromal antigen 2 (STAG2) [31].
Here, we focus on tumor-secreted exosomes and their miRNA cargo as an alternative
communication channel between the tumor, immune, and nerve cells. Recent research has highlighted
the impact of tumor-derived exosomes on the immunosuppressive TME and on tumor-associated
nerve cells.
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2. Communication between Nerve Cells and Cancer Cells
2.1. Nerves within the Tumor Microenvironment Can Either Promote or Inhibit Tumorigenesis
The autonomic nervous system is the part of the peripheral nervous system which maintains body
homeostasis by relaying information between the central nervous system (CNS) and the periphery
(sensors and effectors) [32]. The autonomic nervous system is further divided in the sympathetic (SNS)
and parasympathetic nervous systems (PSNS). Both the SNS and PSNS have an afferent nerve fibers
connected to special sensory organs (nociceptors, chemosensors, pH sensors) and an efferent component
honing on effectors represented by smooth muscles, cardiac muscles and glands. The specific cellular
architecture of the autonomous afferents consists of a series of two neurons connected within peripheric
ganglions: a preganglionic neuron originating within the CNS, and a postganglionic neuron linked
to effectors. The unique localization of postganglionic neurons outside the CNS but also outside the
tissue they innervate have two important consequences: on the one hand, being outside the CNS,
postganglionic neurons are in a position to adapt their transcription, translation and cytoskeletal
dynamics to the TME they innervate independently of the CNS. Similarly, emerging evidence suggest
that sensory neurons and the TME exert mutual influence on each other [33]. On the other hand,
because of the location of postganglionic neuron bodies outside the malignant tissue, studies focusing
on the malignant tissue itself fail to capture the molecular signals of postganglionic neurons, resulting
in an underappreciation of their effect on the TME. SNS and PSNS exert their function through a series
of specific transmitters and cognate receptors. A summary of the adrenergic and cholinergic receptor
subtypes, effectors and ligands is presented in Table 1.
Table 1. Summary of adrenergic and cholinergic receptor subtypes, effectors and ligands.
Receptor Subtype Effector Ligand
Adrenergic receptors (AR)
alpha 1 Gq: ↑PLC, ↑PIP3, ↑DAG, ↑Ca2+ adrenaline, noradrenaline
alpha 2 Gi: ↓AC, ↓cAMP adrenaline, noradrenaline
beta 1 Gs: ↑AC, ↑cAMP adrenaline, noradrenaline
beta 2 Gs: ↑AC, ↑cAMP adrenaline, noradrenaline
beta 3 Gs: ↑AC, ↑cAMP adrenaline, noradrenaline
Cholinergic receptors
Nicotinic ↑Na+, ↑K+ acetylcholine, nicotine
Muscarinic M1 Gq: ↑ PLC, ↑PIP3, ↑DAG, ↑Ca2+ acetylcholine, muscarine
Muscarinic M2 Gi: ↓AC, ↓cAMP acetylcholine, muscarine
Muscarinic M3 Gq: ↑ PLC, ↑PIP3, ↑DAG, ↑Ca2+ acetylcholine, muscarine
Muscarinic M4 Gi: ↓AC, ↓cAMP acetylcholine, muscarine
Muscarinic M5 Gq: ↑ PLC, ↑PIP3, ↑DAG, ↑Ca2+ acetylcholine, muscarine
Gi = G-protein alpha subunit, group S; Gs = G-protein alpha subunit, group S; Gq = G-protein alpha subunit,
group Q; PLC = phospholipase C; AC = adenylate cyclase; DAG = diacylglycerol; PIP3 = phosphatidylinositol
3,4,5 trisphosphate.
In addition to being neurotransmitters, adrenaline and noradrenaline are also stress hormones
released systemically by the adrenal medulla [34]. In fact, the adrenal medulla can be considered as a
specialized sympathetic ganglion as it is innervated by preganglionic nerve fibers. Unlike sympathetic
ganglia, the adrenal medulla lacks synapses and its secretions are released directly into the blood [35].
Thus, the role of autonomous nervous system (sympathetic and parasympathetic signaling) must be
understood in the broader context of adaptation to stress, which involves both nerves and hormones.
Nerves and blood vessels often travel in tandem as neurovascular bundles and both play crucial
roles in the development and maintenance of organs. Not unexpectedly, an increase in blood vessel and
nerve density is a hallmark histological change in cancer. Conceptually, there is a distinction between
cancer-induced growth of nerves and nerve-induced growth of cancer cells. On the one hand, cancer
cells induce neuritogenesis (formation of neurits), which can further develop into axons (axonogenesis
= sprouting of new nerve fibers) and, more rarely, neurogenesis (proliferation of neurons). On the
other hand, nerves can stimulate tumor progression by forming a positive feedback loop within the
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TME [36]. The invasion of nerves by malignant cells is termed perineural invasion (PNI) [37]. PNI is a
marker of unfavorable outcome and is associated with shorter overall survival (OS) in gastric, colon,
rectal, prostate, esophageal, biliary tract, head and neck, and other cancers [4,38–43]. In addition to
having a prognostic role, PNI was proposed as an indication for a more aggressive treatment approach,
like radiotherapy, in head and neck cancers [44].
Early evidence concerning the nerve-tumor relationships emerged from tumor denervation studies
suggesting that nerves within the TME can either promote or inhibit tumorigenesis depending on
tumor type. Thus, surgical transection of the vagus nerve (which severs both parasympathetic and
sensory axons in this mixed nerve) accelerates progression from pancreatic intraepithelial neoplasia
to pancreatic ductal adenocarcinoma (PDAC) [45,46], while in gastric cancer, the surgical transection
of the vagus nerve has anti-tumorigenic effects [47]. The difference stems from the fact that most
gastric cancers are adenocarcinoma arising from the glandular epithelium that receive cholinergic
afferents, while PDACs are derived from the ductal epithelium receiving a great deal of adrenergic
innervation. In vivo studies in prostate cancer showed that both the sympathetic and parasympathetic
nerves of the TME can promote tumorigenesis. The sympathetic nerve fibers regulate the initial growth
phase of prostate cancer via the β 2 and β3 adrenergic receptors (AR) on stromal cells, while the
parasympathetic fibers control invasion and metastasis via type 1 muscarinic acetylcholine receptor
(M1-AChR) on stromal cells [48].
Dissecting the specific contribution of sympathetic and parasympathetic afferents as well as of
sensory autonomous neurons to cancer onset and progression requires a variety of strategies involving
genetic manipulation (i.e., transgenic mice), optogenetics, neurotoxins, pharmacological modulation,
and surgical denervation [49]. Using chemical denervation of the sensory component of the vagus nerve,
a clear anti-tumorigenic effect of sensory autonomous nerves in PDAC emerged [33,50,51]. The emerging
landscape suggests that adrenergic and autonomous sensory neurons have a pro-tumorigenic effect in
solid malignancies, while the effect of parasympathetic signaling is cancer-type dependent (Table 2).
The situation differs, however, in the case of hematological malignancies, where adrenergic signaling
has an anti-tumorigenic effect.
Table 2. The relationship between cancer type and the effect of sympathetic and parasympathetic innervation.
Cancer Type Sympathetic Innervation Parasympathetic Innervation References
Lung Cancer Pro-tumorigenic Pro-tumorigenic [52–55]
Gastric cancer Pro-tumorigenic Pro-tumorigenic [47,56–59]
Colorectal Cancer Pro-tumorigenic Pro-tumorigenic [60–63]
Pancreatic ductal adenocarcinoma Pro-tumorigenic Anti-tumorigenic [46,64]
Prostate cancer Pro-tumorigenic Pro-tumorigenic [65–68]
Breast cancer Pro-tumorigenic Anti-tumorigenic [69,70]
Hematological malignancies Anti-tumorigenic Anti-tumorigenic [71–74]
An extensive body of evidence demonstrated that adrenergic signaling has pro-tumorigenic
effects in lung cancer (reviewed in [52]). In NSCLC, Nilsson and colleagues described a mechanism
of resistance to anti-epidermal growth factor receptor (EGFR) inhibition involving beta 2-adrenergic
receptors (β2-AR) signaling [53]. The authors showed that adrenaline activates β2-AR on NSCLC
cells, which cooperatively signals with mutant EGFR to induce IL-6 expression through the tumor
suppressor, liver kinase B1 (LKB1). Similarly to adrenergic signaling, cholinergic signaling also has
pro-tumorigenic effects in lung cancer (reviewed in [54]) and the density of both types of nerve fibers is
associated with a worse outcome in lung adenocarcinoma [55]. Zhao et al. have shown that biochemical
events downstream M2AChR activation include the activation of NF-κB p65, which drives migration
and invasion and promotes EMT.
In gastric cancer, both sympathetic and parasympathetic signaling was shown to have
pro-tumorigenic effects. The pro-tumorigenic effects of adrenergic signaling is mediated through
several signaling pathways stemming from β2-AR, including the extracellular signal-regulated
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kinases 1/2 (ERK1/2), c-Jun N-terminal kinases (JNKs) and mitogen-activated protein kinase (MAPK)
pathways. The transcription factors mediating the pro-tumorigenic effect downstream of β2-AR include
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), activator protein 1 (AP-1),
cAMP response element-binding protein (CREB) and (signal transducer and activator of transcription
3) STAT3 [56] and while AMP-activated protein kinase (AMPK)-dependent autophagy was also shown
to [57]. In addition, catecholamine-induced β2-AR activation mediates desensitization of gastric cancer
cells to EGFR antibodies (transtuzumab) by upregulating Mucin 4 (MUC4) expression [58]. In regard
to cholinergic signaling, Zhao et al. reported that the pro-tumorigenic effects of cholinergic signaling
takes place via M3 receptor–mediated Wingless and Int-1 (Wnt) signaling in the stem cells [47] while
Hayakawa et al. reported that acetylcholine stimulates tumor growth via its M3-AChR, activating
yes-associated protein (YAP), a modulator of Wnt/β-catenin signaling [59].
The pro-tumorigenic effects of adrenergic signaling in colorectal cancer is dependent on EGFR- protein
kinase B (PKB/Akt)/ERK1/2 signaling [60], while Han et al. unveiled a norepinephrine-CREB1-miR-373 axis
that promotes the progression of colon cancer by downregulating tissue inhibitor of metalloproteinases
(TIMP2) and adenomatous polyposis coli tumor suppressors [61]. Similarly, to adrenergic and noradrenergic
signaling, muscarinic cholinergic signaling has pro-tumorigenic effects in colorectal cancer by transactivating
EGFR (reviewed in [62]). In addition, pro-tumorigenic cholinergic signaling is also triggered by conjugated
secondary bile acids such as lithocholyltaurine [63].
An extensive body of evidence suggests that in PDAC, sympathetic signaling has a pro-tumorigenic
effect while parasympathetic signaling has an anti-tumorigenic effect. Xiao et al. substantiated the
pro-tumorigenic effects of sympathetic signaling in PDAC by showing that β2-AR regulates the
expression of aldo-keto reductase family 1 member B (AKR1B1) in human pancreatic cancer cells and
promotes their proliferation via the ERK1/2 pathway [64]. In contrast, cholinergic signaling directly
and indirectly suppresses pancreatic tumorigenesis and cancer stemness via muscarinic receptors.
The anti-tumorigenic effect of cholinergic muscarinic signaling is achieved in part through CHRM1
and downstream effectors MAPK/EGFR and (phosphoinositide 3-kinase) PI3K/AKT [46].
In prostate cancer, both sympathetic and parasympathetic signaling has pro-tumorigenic effects.
β2-AR signaling promotes proliferation and migration of prostate cancer cells via β-arrestin 2-mediated
increase in cAMP levels and ERK1/2 activation [65]. In regard to parasympathetic signaling, M1-AChR
mediates prostate cancer cell migration and invasion through hedgehog signaling [66], M3-AChR
activates actin cytoskeleton and the MAPK signaling pathways [67]. In addition, M1-AChR and
M3-AChR receptors promote castration-resistant growth of prostate cancer through a focal adhesion
kinase (FAK)-YAP signaling axis [68].
In breast cancer it was shown that the SNS via β2 adrenergic signaling increases the infiltration
of macrophages into the tumor environment. The infiltrating macrophages induce the expression of
pro-metastatic molecules: Tgfb, Mmp9, Vegf, Vcam1, Csf1, Arg1 and Ptsg2. Collectively, these changes
increase the metastatic burden in a murine breast cancer model [69]. The anti-tumorigenic effect of the
sensory nerve was described in a mouse model of breast cancer. Capsaicin-induced depletion of sensory
neurons resulted in the downregulation of Caspase-7 (an executor of apoptosis) and a disintegrin
and metalloproteinase domain-containing protein 10 (ADAM-10). The pro-tumorigenic effects of
ADAM-10 downregulation are explained by the fact that ADAM-10 actually hydrolyzes substance
P to growth-inhibitory products, so that the loss of ADAM-10 exhausts an important tumorigenic
suppressor [70].
In contrast to epithelial solid malignancies in which data on sympathetic signaling converge
on a pro-tumorigenic effect, sympathetic signaling seems to portend an anti-tumorigenic effect
in hematological malignancies. Hanoun et al. reported that the disruption of β2 adrenergic
signaling promotes leukemic bone marrow infiltration in vivo [71]. In addition, development of
acute myeloid leukemia disrupts SNS nerves and the quiescence of Nestin+ niche cells, leading to an
expansion of phenotypic mesenchymal progenitor and stem cells primed for osteoblastic differentiation,
at the expense of hematopoietic stem cell-maintaining neural/glial antigen 2 positive (NG2+)
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periarteriolar niche cells. The disruption of bone marrow adrenergic innervation is also responsible for
chemotherapy-induced impairment of hematopoiesis [72]. In regard to parasympathetic signaling,
in vitro data suggest that cholinergic signaling has anti-tumorigenic effects in chronic myelogenous
leukemia cell lines through nicotinic and muscarinic type cholinergic receptors [73,74].
Similarly, to adrenergic signaling, a duality between solid epithelial and hematological
malignancies seems to exist in regard to glucocorticoids, which are another class of major stress
hormone. Glucocorticoids are potent anti-tumorigenic agents in hematological malignancies while in
solid malignancies the effect is dependent on cancer type [75]. In fact, potent synthetic glucocorticoids
such as prednisone and dexamethasone are often part of chemotherapy regimens in hematological
malignancies (in particular lymphoid malignancies) (reviewed in [76]).
Emerging evidence suggests that the nerve-tumor relationship recapitulates developmental
programs of organogenesis. The morphogenesis of the embryonic submandibular gland is one of the
most studied ex vivo system which captures the key relations between developing organs and nerves
and which offers unique insights into the molecular mechanisms taking place within tumors [77].
The submandibular salivary gland achieves the necessary functional surface of secretory epithelium
through a series of branching and budding orchestrated by the relation between the developing organ
and nerves. Thus, the embryonic epithelial mesenchyme recruits nerves by secreting neurotrophic
factors. In mammals, the neutrophin family has four members: nerve growth factor (NGF), which is
the prototype neurotrophyn [78], brain-derived neurotrophic factor (BDNF), neurotrphin-3 (NT-3) and
NT-4. The neutrotrophin family of NGF has both a high affinity receptor (tropomyosin-related kinase
A (TRKA)) and a low-affinity p75 neurotrophin receptor (p75NTR) [79]. Another important family of
neurotrophic factors is glial cell-derived neurotrophic factor (GDNF) family which includes artemin,
neurturin (NRTN) and persephin, the cognate receptor being GDNF family receptor (GFR).
During the embryologic development of the submandibular gland, the epithelial end-buds and
ducts secrete neurturin, which binds neuronally expressed GFRα2 and triggers axonal outgrowth
from the parasympathetic submandibular ganglion [80]. Parasympathetic nerves in turn release
acetylcholine, which activates SRY-box 2 (SOX2)+ epithelial progenitors through muscarinic receptors,
inducing acinar bud branching and maturation [81]. Similar mechanisms of gland development
involving both PSNS and SNS have been described in the developing pancreas and limbs as well as
during limb regeneration [82–85].
A growing body of evidence suggests that tumors coopt nerves for recapitulating the
developmental programs of organogenesis. Thus, cancer cells establish a cancer-promoting feedback
loop by stimulating axonogenesis or neuritogensis within the TME. In fact, a series of observational
studies suggest that cancer cells are able to release neurotropic factors that stimulate axonal
sprouting [36]. For instance, GDNF and other members of the GDNF family (artemin, NRTN and
persephin) were shown to play important cancer promoting roles in pancreatic cancer [86]. Wang et al.
observed that pancreatic cancer cells synthesize and release neurturin. Simultaneously, it was observed
that the nerve fibers around tumor cells have an increased expression of GFRα-2, the specific receptor
for NRTN. The tissue immunoreactivity for GFRα-2 directly correlated with a more severe pain
phenotype in pancreatic cancer patients. In vitro matrigel-based invasion assay showed that NRTN
enhances the invasiveness of pancreatic cancer cells and that it induces neuritogenesis of ex vivo
dorsal root ganglions [87]. Similarly, Ceyhan et al. showed that pancreatic cancer and the surrounding
non-cancerous pancreatic tissue exhibit an increase in nerve density compared to normal pancreatic
tissue from control subjects. NGF and artemin expressions significantly correlated with neural
hypertrophy and density. Finally, the authors showed that tissue extracts from pancreatic cancer as well
as from the surrounding normal pancreatic tissue stimulate neuritogenesis in myenteric plexus-cultures,
an effect which was abrogated by depletion of artemin and/or NGF [88].
A cancer promoting feedback loop by which cancer cells coopt nerves within the TME, which in
turn paves the way for cancer growth and invasion was also described in prostate and in gastric
cancers. Hayakawa et al. studied the interplay between nerves and gastric cancer cells and discovered
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that the main acetylcholine source in gastric cancer are nerve cells and chemosensory Tuft cells
from gastric crypts. In turn, acetylcholine produced by these cells up-regulates NGF in cancer cells.
In a feedback loop mechanism, NGF further increases nerve growth which promotes tumorigenesis.
Mechanistically, it seems that acetylcholine stimulates tumor growth via its muscarinic acetylcholine
receptor-3, activating YAP, a known modulator of Wnt/β-catenin signaling [59]. Prostate cancer cells
contain higher levels of the precursor of NGF (proNGF) compared with benign hyperplastic cells.
Clinically, the expression of proNGF significantly correlated with grade (i.e., the Gleason score) and
further functional studies revealed that prostate cancer cell lines co-cultured with neurons can induce
neurite outgrowth [89]. Interestingly, Dobrenis et al. highlighted the link between immune system and
nerves in tumor progression. Granulocyte colony-stimulating factor (G-CSF) does not only stimulate
the myeloid lineage, but it is also a neurotropic growth factor. In prostate cancer, G-CSF promotes
the growth of both sympathetic and parasympathetic nerve fibers in the TME and the nerves further
increase the metastatic potential of this tumor type [90]. Although the downstream effectors which
mediate nerve-induced cancer growth are still being explored, these observational studies demonstrate
that cancer hijacks developmental programs involving the autonomous nervous system.
In a seminal paper by Claire Magnon and collaborators [91], the authors discovered that de novo
functional neurons from the subventricular zone of the central nervous system migrate through the
blood and infiltrate the tumor stroma or metastatic tissue of prostate cancer, where they differentiate
into adrenergic neurons. Thus, the authors described the presence within the TME of prostate cancer of
nerve cells expressing doublecortin (DCX+), which is a classical marker of neural progenitors from the
central nervous system. The high density of DCX+ cells are associated with an unfavorable outcome.
In the periphery, DCX+ progenitor cells are capable to stimulate tumor initiation, tumor growth,
and metastasis of prostate cancer cells [91].
2.2. Exosomes Are Key Components of the Communication between Nerve and Cancer Cells
The role of exosomes in the crosstalk between tumor cells and the nerves within the TME started
from the observation that head and neck cancers are intensely innervated by autonomous sensory
nerves and the degree of innervation is associated with decreased survival. Next, the authors employed
a rat pheochromocytoma cell line, as an in vitro assay of neuritogenesis and observed that plasma
exosomes from cancer patients or exosomes derived from tumor cells induced a significant neurite
outgrowth while plasma exosomes from healthy donors or tonsil exosomes had a limited capacity to
induce neurite outgrowth. Furthermore, in a series of elegant in vivo experiments, it was confirmed
that tumor exosomes can induce neurite outgrowth. Mechanistically, the authors showed that the
induction of neurite outgrowth by exosomes was not dependent on either NGF or BDNF, NT-3,
NT-4 or GDNF. Instead, the authors discovered that erythropoietin-producing human hepatocellular
(Eph) receptor-interacting proteins B1 (EphrinB1) packed into exosomes potentiated the growth
of peritumoral nerve fibers. EphrinB1 is an axonal guidance molecule with important function
in embryonic development that has the capacity to redirect axonal trajectory via the Ehp receptor.
Importantly, the neuritogenesis-inducing capacity of exosomes from EphrinB1 null cancer cells is
not completely abolished, suggesting that neuritogenesis induction takes place through a yet to be
discovered mechanism. Nonetheless, the authors provided evidence that the process is dependent
on MAP kinase signaling. Finally, the authors extended their observations in colorectal cancer,
breast cancer, and melanoma, suggesting that exosome-mediated neurite outgrowth is important across
cancer types [92]. In a subsequent study, the authors reported a similar exosome-based cancer-nerve
communication operating in the case of cervical carcinoma [93].
Additional evidence linking exosomes to neurite outgrowth was provided by Ching et al.,
who showed that RNA molecules are key players in this process. The authors isolated exosomes
from primary Schwann cells and adipose-derived stem cells differentiated towards a Schwann cell
phenotype (dADSC) and observed that these exosomes were able to induce neurite outgrowth in vitro.
When analyzing the exosome content, it was noticed that five miRNAs were overexpressed in exosomes
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from dADSC and in Schwann cells compared to undifferentiated stem cells: miR-18a, miR-182,
miR-21, miR-222, and miR-1. Additionally, two mRNAs with important roles in neural growth were
upregulated in exosomes from dADSC: GAP43 and Tau. The authors hypothesized that these RNA
molecules are responsible for the neurite outgrowth induced by exosomes from Schwann/Schwann-like
cells [94].
In a recent publication, we characterized the crosstalk between head and neck cancer cells and the
nerve fibers of the peripheral nervous system. We observed that loss of p53 induces a significant increase
in nerve fibers in the TME and this phenomenon is associated with an unfavorable outcome. In an
attempt to explore the mechanism that induces neuritogenesis, we observed that the growth of neural
filaments of dorsal root ganglia (DRG) is controlled by exosomes released from p53 null head and neck
cancer cells and not by exosomes from p53 WT cells. After characterizing the content of the exosomes,
we noticed that the EVs from p53 null cells were depleted of the p53 regulated miRNA, miR-34a,
compared to those from p53 WT cells. Additionally, exosomes released from miR-34a-5p deficient p53
WT cells lost their capacity to inhibit neuritogenesis. Regarding the mechanism that stimulates the
growth of nerve fibers, we showed that miR-21 and miR-324, which are up-regulated in exosomes
from p53 null cells, were responsible of this stimulatory signal. Moreover, the exosomes from p53 null
cells not only increased the number of nerve fibers, but also induced the reprogramming of sensory
nerves. In vivo studies revealed that exosomes from p53 null cells were capable to transdifferentiate
sensory nerves to adrenergic nerves which further promote the growth of the tumor, thereby forming a
positive feedback mechanism [95].
Taken together, these data support the concept that nerve cells and nerve fibers play an
important role in tumorigenesis and that exosome communication and their RNA content contribute
to this cross-talk.
3. Communication between Immune Cells and Cancer Cells
3.1. The Immunological Landscape of Tumors Dictates the Outcome of Cancer Patients
The immune system plays a crucial role in cancer onset and progression, and it can be exploited
as a therapeutic strategy [96]. The advent of immunotherapy, which proved to be game changer
in a number of immunologically “hot” cancer types such as melanoma [97] or lung cancer [98],
have sparkled interest towards the possibility of extending their use on all cancer types. However,
many tumors are intrinsically immunologically “cold” and fail to respond to immunotherapy. Thus,
the goal is to understand the molecular mechanisms which distinguish immunologically ‘cold’ tumors
and to find ways to rekindle the immunogenicity of the tumors.
The quest towards understanding the molecular mechanism behind the impaired immune
response in cancer starts with the evolution of the tumor. Indeed, the immune system imposes an
evolutionary constraint on the tumor growth, altering its natural genotypic and phenotypic trajectory,
a phenomenon termed immunoediting [99]. Transformed cells develop escape mechanisms of resisting
the control of the immune system (i.e., tumor-dependent escape) [100]. Alternatively, tumors dampen
immunity by imposing an immunosuppressive state within the TME (i.e., immune system-dependent
escape) [101]. Importantly, both innate and adaptive immunity are the culprits for the failure of
the immune system to keep under control the malignant growth and for the establishment of an
unfavorable immune landscape.
3.2. Communication between Tumor Cells and Adaptive Immunity Is both Direct and Exosome-Mediated
Adaptive immunity has been the focus of immunotherapy due to the immense success of chimeric
antigen receptor T cells (CAR-T cells) and check point inhibitors in the treatment of a subset of cancer
types with favorable immune landscape. For instance, the five-year survival of advanced melanoma
patients treated with a combination of ipilimumab and nivolumab exceeded 50% [102]. The number of
therapeutic strategies leveraging the immune system has expanded tremendously in the past years.
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For the moment, approved immunotherapies include the oncolytic virus talimogene laherparepvec
for melanoma [103], the dendritic vaccine Sipuleucel-T for prostate cancer [104], two CD19 targeting
CAR-T cells for acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL) [105],
and seven checkpoint inhibitors targeting either the PD1/PD-L1 or CTLA-4/B7-1/B7-2 axis (reviewed
in [106]). Additional forms of immunotherapy are currently under investigation.
The activation of the immune system must intrinsically limit itself to prevent triggering
autoimmunity. This state of balance is often referred to as Th1/Th2 paradigm, which states that
Th1 cells promote a proinflammatory phenotype and Th2 cells orchestrate an immunosuppressive
phenotype [107]. In cancer, the equilibrium is aberrantly tilted towards the immunosuppressive
phenotype and the goal of immunotherapy is to reverse it. The main mechanism of maintaining
immunological homeostasis is based on direct cell-to-cell interaction.
In the activation of T cells, the key molecular event is represented by the engagement of the T-cell
receptor (TCR) by the processed antigen displayed on the MHC-I/II molecules. However, this event
by itself is not enough for T cell activation, and the process is regulated by several co-stimulatory
and co-inhibitory molecular signals (generally termed co-signaling). The B7-1/B7-2-CD28 is the
prototype co-stimulatory axis in TCR signaling [108], while PD1-PD-L1/2 and CTLA-4 are the most
well understood co-inhibitory axes [109,110]. The engagement of CD28 expressed on T cells by B7-1
(CD80) and B7-2 (CD86) on antigen presenting cells (and other cells) results in downstream activation
of the PI3K and AKT signaling pathways which drive T cell activation [111,112]. In addition, CD28
also mediate some of the activating effect resulting from TCR engagement. Importantly, CTLA-4 axis
operates mainly at sites of T-cell priming (e.g., secondary lymphoid organs), where B7/CD28-mediated
co-stimulation is also prominent. In contrast, the PD1-PD-L1/2 axis operates mostly in non-lymphoid
tissues and dampens T cell activation in the periphery [113].
Besides direct cell-to-cell communication, exosomes and EVs are emerging as key factors
modulating adaptive immunity within the TME [114]. Maybruck et al. showed that head and neck
cancer cells induce a suppressor phenotype in human CD8 T-cells via an exosomal immunomodulatory
protein, galectin-1 (Gal-1) [115]. Exosomes derived from melanoma cells were shown to be enriched
for a subset of coding and non-coding RNAs, most notably mmu-miR-709. These exosomes altered
mitochondrial respiration and upregulated genes associated with the Notch signaling pathway in
cytotoxic T cells [116].
3.3. Exosomes Are Key Components of the Communication between Innate Immunity and Cancer Cells
Besides adaptive immunity, it is becoming increasingly apparent that innate immunity plays
a crucial role in determining the evolution of cancer. Importantly, innate and adaptive immunity
are not independent but intertwined and an impaired innate immunity in the TME will ultimately
result in aberrant adaptive immunity. Innate immunity cells governing the TME include macrophages,
DCs, neutrophils, myeloid-derived stem cells (MDSCs), and natural killer cells (NKs). In each case,
cell subtypes resembling the Th1/Th2 paradigm have been delineated.
In the bloodstream, there are two major types of monocytes, classical “inflammatory”
and non-classical, patrolling monocytes (PMo), performing pro-tumoral and anti-tumoral functions
depending on cancer type/tissue of origin, differences in TME, stage of tumor growth and
the experimental model and, most probably, on the tumor-secreted exosomes cargo [117,118].
Circulating monocytes extravasate into the tissue and differentiate into macrophages. Macrophages
within the TME, termed tumor associated macrophages (TAMs), can compose up to 50% of the tumor
mass [119]. Macrophages can be polarized into inflammatory M1 macrophages (classically activated)
and M2 macrophages with immunosuppressive function (alternatively activated) [120]. Macrophages
exert their main immune function by pathogen phagocytosis and antigen presentation, but also
contribute to wound healing and tissue repair. Most TAMs are polarized towards the M2 phenotype
and is associated with negative prognosis as well as treatment resistance [121]. The M2 phenotype
is promoted by cytokines and hypoxia present in the TME. For instance, IL-4, abundantly present in
J. Clin. Med. 2020, 9, 3529 11 of 25
the TME, promotes an M2 phenotype via STAT6 signaling (alternative activation) [122]. The wound
healing and tissue repair functions of macrophages are exploited by the cancer cells to instead promote
tumor growth, angiogenesis, and EMT [123].
Cancer-derived exosomes can induce both immunosuppressive or immunogenic phenotypes
in surrounding monocytes and macrophages. For instance, exosomes secreted by non-aggressive,
poorly metastatic melanoma block experimental lung metastasis by increasing the expansion of the
PMo population in the lungs [124]. In support of the deleterious effect of cancer-derived exosomes,
Kanlikilicer et al. unveiled a resistance mechanism to paclitaxel in ovarian cancer based on the
exosomal transfer of oncogenic miR-1246 to M2-type macrophages, which results in the upregulation of
multidrug resistance protein 1 (also called p-gp, MDR1 or ABCB1) [125]. Similarly, Cooks et al. showed
that p53-mutant colon cancer cells, selectively shed miR-1246-enriched exosomes. When exosomes fuse
with neighboring macrophages, the macrophage function is reprogrammed into a cancer promoting
state with increased TGF-β activity [126].
Park et al. focused on the molecular mediators of tumor hypoxia across multiple tumor types [127].
They found that hypoxia induces the secretion of exosomes with the ability of promoting an M2-like
phenotype and modifying the immunometabolic profile of infiltrating macrophages via let-7a miRNA,
thus demonstrating a mechanism by which exosomal cargo allows tumor cells to influence the behavior
of infiltrating immune cells [127].
The cross-talk between cancer cells and macrophages is bidirectional. In PDAC, macrophage-derived
exosomes (MDE) significantly decreased the sensitivity of PDAC cells to gemcitabine, both in vitro
and in vivo. This effect was mediated by transfer of oncogenic miR-365 to PDAC cells via exosomes,
which resulted in upregulation of the triphosphonucleotide pool in cancer cells and the induction of the
enzyme cytidine deaminase, whose effects is to inactivate gemcitabine [128]. Similarly, Challagundla et
al. reported a mechanism of chemotherapy resistance in neuroblastoma (NBL) cells based on exosomal
miRNAs exchanged between cancer cells and the neighboring monocytes [129]. The authors suggested
that NBL cells transfer miR-21, which in turn upregulates miR-155 in monocytes through a TLR8
dependent mechanism and polarizes them towards an immunosuppressive M2 macrophage phenotype.
MiR-155 is then transferred from monocytes to NBL cells via exosomes, resulting in the downregulation of
TERF1, which in turn mediates resistance to cisplatin. This signaling circuitry seems to take place between
NBL and monocytes but not between NBL and DC. The use of an inhibitor of exosome generation
(GW4869), in fact, restores NBL cell drug sensitivity, even in the presence of surrounding monocytes,
demonstrating the importance of exosomes as a potential therapeutic target [129].
MiRNA transfer between cancer cells and surrounding macrophages also takes place in a paracrine
manner. Frank et al. provided evidence that miR-375 released by breast cancer cells during apoptosis
could be involved in the modification of macrophages towards a tumor-supportive phenotype [130].
The results showed that macrophages take up miR-375 via CD36, which directly targets TNS3 and PXN
enhancing macrophage migration and infiltration. In another study, Chen et al. found that miR-940,
released via exosomes by ovarian cancer cells, targeted TAMs and promoted tumor growth via the
CD206 and CD163 pathways [131].
MDSC are a heterogeneous population of immature macrophages, immature granulocytes,
and immature DC [132]. MDSC present in the TME adopt an immunosuppressive phenotype,
enhance tumor cell stemness, angiogenesis, and EMT, through IL-6 [133]. Glioma-derived exosomes
(GDEs) influence the differentiation and activation of MDSC, as shown in a study centered on the
role of GDEs in potentiating MDSC development [134]. GDEs induced a stronger MDSC expansion
under hypoxic conditions, as compared to normoxia. Moreover, hypoxia induced miR-10a and
miR-21 expression in GDE, which mediated MDSC expansion and activation by targeting RAR-related
orphan receptor alpha (RORA) and phosphatase and tensin homolog (PTEN) pathway. In addition,
GDE activate the pro-proliferative and immunosuppressive functions of MDSC in vitro and in vivo by
exosomal transfer of miR-29a and miR-92a, which target high-mobility group box transcription factor 1
(Hbp1) and protein kinase cAMP-dependent type I regulatory subunit alpha (Prkar1a) [135].
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NKs are circulatory innate lymphoid cytotoxic effector cells which eliminate cancer cells
and limit metastases using death receptor-mediated apoptosis and perforin/granzyme-mediated
cytotoxicity [136]. Consequently, low NK cell activity is associated with an increased cancer risk [137].
The cancer-killing capacity of NKs is impaired within the TME because of soluble factors and membrane
encapsulated molecules [138]. Trying to understand how the TME-associated factors contribute to a
drug-resistant phenotype in NBL, Neviani et al. described the role of NKs’ exosomes in the interplay
between cancer cells and the TME. They showed that the cytotoxicity of NK exosomes depends not
only on the presence of canonical killer molecules (i.e., perforin 1, granzyme A and B), but also on their
nucleic acid cargo. In high risk NBL, the tumor suppressor miR-186, present in NK-derived exosomes,
is downregulated. Exosomal delivery of miR-186 to NBL and NK cells impaired the survival and
migration of NBL cells both in vitro and in vivo. Moreover, modulation of miR-186 abundance in these
exosomes altered the NKs’ cytotoxic potential, suggesting that this miRNA may be at least in part
responsible for their cytotoxic activity, highlighting the therapeutic potential of NK-derived exosomes
in overcoming tumor growth [139].
DCs are antigen presenting cells (APCs) which bridge the gap between adaptive and innate
immunity. DC present in the TME are referred to as tumor-infiltrating DC (TIDC). DC are broadly
classified into classical, plasmacytoid DC, and monocyte-derived inflammatory DC [140]. DC and
TIDC exhibit phenotypic plasticity and can both have immunogenic and immunosuppressive functions.
Thus, TIDS are associated with a positive prognosis in endometrial carcinoma but a negative prognosis
in breast cancer [141,142]. In addition, the immunosuppressive phenotype of TIDS usually accompanies
more advanced forms of cancer. The culprits for polarizing TIDC towards an immunosuppressive
phenotype include factors such as VEGF, IL-10, TGF-beta, and PGE2, leading to the activation of the
indoleamine-pyrrole 2,3-dioxygenase (IDO), arginase 1 (Arg1), inducible nitric oxide synthase (iNOS),
and STAT3 pathways and tilting the equilibrium towards Th2 activation [119]. Being professional APCs,
DCs express a wide range of TLRs and cytokines, which play an important role in activation of immune
response. However, though stimulation from the TME, DCs shift from effective antigen presenting
cells into negative modulators of immune responses. In order to study the impact of exosomes on
TLR4 in dendritic cells, Zhou et al. performed a transfection experiment with miR-203 mimics and
inhibitors on a pancreatic cell line, as miR-203 was previously shown to be upregulated in PDAC.
The results showed that miR-203 mimics could lead to a downregulation of TLR4 compared with the
control group, while miR-203 inhibitors could reverse the downregulation of TLR4, thus suggesting
that tumor-derived exosomes interfere with DCs via miR-203 [143].
In summary, communication between all types of immune and cancer cells and between nerve
and cancer cells exists, and exosomes and their miRNA cargos (Table 3) which could be exploited as a
potential therapeutic target.
Table 3. Exosomes as a communication tool between nerves and cancer cells and between immune and
cancer cells, and the consequently generated effects.
Exosome Origin Target Cells Key Molecules Involved Effect Ref
Head and neck squamous cell
carcinoma cell lines (other cancers:
CRC, BC, melanoma)
PC12 cells (rat
pheochromocytoma cell line) EphrinB1 protein
Neurite outgrowth (in vitro) and tumor
innervation (in vivo). [92]
dADSC, primary Schwann cells NG108–15 neurons
miRNAs: miR-18a, miR-21,
miR-182, miR-222, miR-1,
and mRNAs: GAP43 and Tau
Neurite outgrowth. [94]
p53 null head and neck cancer cells Peritumoral nerve fibers,DRGs and TGs
Low levels of miR-34a and
high levels of miR-21 and
miR-324
Neurite outgrowth and
transdifferentiation of sensory neurons
in adrenergic neurons.
[95]
Head and neck cancer cells CD8+ T cells Galectin-1(immunoregulatory protein)
Stimulation of CD8+ T-cell suppressor
phenotype. [115]
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Table 3. Cont.
Exosome Origin Target Cells Key Molecules Involved Effect Ref
Melanoma cell lines CTLL2 Cytotoxic T cell lines
miR-709, miR-2137,
miR-2861, miR-1195,
miR-762 (the five most
highly abundant miRNAs)
Transcriptome signature changes
resulting in mitochondrial respiration
alteration.
[116]




PMo conditioned innate immune
response with cancer cell clearance at
the metastatic niche.
[124]
Neuroblastoma cell lines Monocytes miR-21




Ovarian cancer cell lines Macrophages miR-1246
Transfer of oncogenic miR-1246 to
M2-type macrophages, but not M0-type
macrophages.
[125]
p53 mutant CRC cells Macrophages miR-1246
Macrophage miR-1246-dependent
reprogramming into a cancer promoting
state with increased TGF-beta activity.
[126]
Melanoma cell lines Macrophages let-7a
Macrophage increased oxidative
phosphorylation activity and M2-like
polarization.
[127]
Glioma cell lines under hypoxic
conditions MDSC miR-10a and miR-21
Hypoxia-inducible expression of
miR-10a and miR-21 mediates MDSC
expansion and activation by targeting
RORA and PTEN.
[134]
Glioma cell lines MDSC miR-29a and miR-92a




Pancreatic adenocarcinoma cell lines DC miR-203 Downregulation of TLR4 anddownstream cytokines. [143]
dADSC—Adipose derived stem cells were differentiated towards a Schwann cell-like phenotype;
MDSCs—Myeloid-derived suppressor cells; DC—Dendritic cells; DRG—dorsal root ganglia; TG—trigeminal
ganglia; CRC—colorectal cancer; BC—breast cancer; PMo—patrolling monocytes; RORA, RAR-related orphan
receptor alpha; PTEN, phosphatase and tensin homolog.
4. Is There any Communication between Nerves and Immune Cells in the Tumor Microenvironment?
We hypothesize that the complex nerve–immune cell interplay takes place both within the TME
(peripheral connection) but also at a systemic level (central connection) (Figure 1). Not much evidence
regarding this interplay exists, but we speculate that exosomes, because of their proven role in the
bilateral communication between cancer cells and nerves and between cancer cells and immune cells,
might also serve as a communication vehicle between nerves and immune cells.
A triple interaction in the periphery, between nerves, blood vessels, and tumor cells, has been
recently unveiled. Zahalka et al. showed that in prostate cancer adrenergic nerve fibers secreting
noradrenalin stimulate the endothelial beta-adrenergic receptor and induce angiogenesis, supporting
tumor growth. Mechanistically, noradrenalin signaling induces a metabolic switch in endothelial cells,
promoting glycolytic metabolism which promotes angiogenesis [144]. A similar triple interaction in
the TME could also exists between cancer cells, nerves and immune cells. Initial evidence in support
of such a mechanism comes from Mo et al., who reported the expression of PD-L1 on peripheral
nerve fibers from the stroma of prostate cancer using a novel monoclonal antibody against PD-L1.
The authors observed that PD-L1 was positively expressed on the nerve branches of 69 out of 73 primary
prostate cancers and that PD-L1 positive nerves were mainly localized in the peritumoral benign
tissue. Moreover, the PD-L1 molecules expressed by nerves seemed to be functional, as the authors
reported a negative correlation between the density of PD-L1 positive nerves and the CD8 tumor
associated lymphocytes. Regarding the clinical implication of PD-L1 on tumor-associated nerves,
it seems that a higher density of the ligand is associated with higher Gleason score, increased PNI,
and poor prognosis [145].
Cavel et al. showed on pathological specimens from patients with PDAC that nerves invaded by
cancer exhibit a high degree of infiltration by CD-68-positive macrophages [146]. The authors were
able to establish a paracrine feedback loop between PDAC and endoneurial macrophages which drives
PNI. PDAC cells recruit endoneurial macrophages by secreting CSF-1, which binds its receptor CSF-1R
on macrophages, resulting in the polarization of macrophages towards a mixed M1/M2 phenotype
via ERK signaling. In turn, activated endoneurial macrophages secrete GDNF, which induces PDAC
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invasion via the GDNF receptor GFRα1 expressed on PDAC cells, MEK-1 and PI3K signalling being
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but molecular mechanisms are needed to be further examined. At the TME level, the interplay between
the three components can be either direct, through ligands, or indirect. We speculate that exosomes
play an important role in this communication both at the systemic level and in the TME.
In PDAC, it was observed that PNI is linked to lower levels of CD8 T cells and Th1 cells and
increased levels of Th2 cells, creating a pro-tumorigenic TME. Mechanistically, nerves invaded by
cancer cells secreted more acetylcholine in the TME. Acetylcholine has a broad role on the immune
phenotype, supporting the differentiation of Th2 cells in favor of Th1, inhibiting the recruitment of
CD8 cells and decreasing the levels of IFN-gamma. These results were further confirmed in a murine
model of sub-diaphragmatic bilateral vagotomy, which resulted in inhibited PNI and tumor growth,
increased Th1 and CD8 cell density, inhibited tumor growth, and prolonged OS [147]. Similarly, it was
noticed that in PDAC, PNI is induced by bone marrow macrophages expressing GDNF ligand that
stimulates tumor cell dissemination along nerves via activating RET [148].
The direct communication between immune cells and nerves via exosomes in the TME has
not yet been described. On the other hand, this type of communication was detected between
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sensory neurons of DRGs and macrophages after nerve injury and this phenomenon partially explains
neuropathic pain. Simeoli et al. have shown that sensory neurons, upon activation, release exosomes
enriched in miR-21-5p. The exosomes containing miR-21-5p are taken up by macrophages inducing a
pro-inflammatory switch. In vivo data further strengthen these findings, as mice with nerve injuries
showed an upregulation of miR-21-5p while the inhibition of the same miRNA reduced neuropathic
pain and recruitment of macrophages with inflammatory phenotype [149].
In summary, these findings make us confident that in cancer, a direct communication between
nerves and immune cells exists and that this is mediated by exosomes. Future studies are necessary to
further describe this interaction.
We also hypothesize that communication between the nervous and the immune systems outside
the TME could influence the oncogenic process. Only limited evidence of this interaction exists.
For example, Frick et al., starting from the concept that stress affects the immune system, observed that
chronic stress alters the T-cell immunity in lymphoma mice. Chronically stressed mice with lymphoma
displayed a reduced T-cell proliferation, lower numbers of CD4 lymphocytes, and lower levels of
TNF-alpha and IFN-gamma. Furthermore, these mice showed an increased proliferation rate of cancer
cells and shorter OS compared to unstressed mice [150]. Although the authors did not delve into the
molecular mechanism underlying this observation, it is likely that stress-related immunosuppression
drives cancer progression via neurotransmitters and even EVs. Indeed, immune cells express β2-AR
and catecholamine-mediated signaling can regulate their function and tumor immune responses.
Norepinephrine secreted by postganglionic sympathetic neurons innervating secondary lymphoid
organs can decrease IFN-gamma and TNF-alpha secretion by primary human CD8+ effector memory
T cells and suppress their cytolytic capacity [151]. Blocking the beta-adrenergic signaling proved to
be effective in improving the efficacy of anti-tumor vaccine by enhancing the frequency of CD8+ T
lymphocytes infiltrating the tumor (TIL). This positive effect mainly occurs in the tumor-draining
lymph node during the initial phase of antitumor CD8+ T-cell priming [152]. The immunosuppressive
potential of MDSCs is also regulated by β2 adrenergic receptor–mediated signaling. In particular,
β2 adrenergic signaling regulates MDSC frequency and survival in tumors, and modulates the
expression of two important immunosuppressive molecules, such as PD-L1 and arginase-I, resulting in
increased suppression of T cell functions [153]. These evidences further confirm the importance
of neuronal infiltration in the regulation of tumor immune responses in the TME. Beside local
delivery of neurotransmitters by tumor-associated neurons, adrenergic signaling can be mediated by
increased norepinephrine systemic levels. In the experimental autoimmune encephalomyelitis model
of multiple sclerosis, β2-AR–mediated signaling was able to reduce the T cell-mediated autoimmunity
in experimental autoimmune encephalomyelitis by suppressing IL-2, IFN-gamma, and GM-CSF
production [154]. This evidence demonstrates the relevant effect of chronic stress in cancer patients,
as it can be associated with increased systemic levels of catecholamine and in turn affects tumor
immune responses.
Nonetheless, other mechanisms like exosomes and EVs can be implicated and need to be further
researched. More recently, Cheng et al., discovered that prostate cancer tumorigenesis is accelerated
by chronic depression in vivo. Depressed mice had more infiltrating TAMs, which were recruited
from the spleen and from circulating MDSC. Furthermore, the authors noticed that the stress hormone
norepinephrine stimulated cancer cells to secrete neuropeptide Y, which further activated myeloid
cells mobilization. In clinical samples, depressed patients had a higher density of TAMs and higher
levels of neuropeptide Y [155].
If this hypothesis is confirmed, it will shed new light on our understanding of cancer as a
systemic disease. Epidemiologic data has already linked psychological trauma with cancer progression
and unfavorable outcomes. In a systematic review analyzing 165 publications, it was proven that
stress-related psychosocial factors increase the incidence of cancer while the analysis of another
330 studies linked stress factors with poor survival [156]. Hence, understanding the systemic
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connection between the immune system and the nervous system will further clarify how behavioral
factors like isolation, depression, and stress play a mechanistic role in tumorigenesis.
5. Future Perspectives
All these data together lead to an important novel therapeutic perspective: simultaneously
inhibiting the nerve and the immune axis that promote tumor progression. In other words, combining
nervous stimulatory signaling blockade with immune checkpoint inhibitors may be an alternative way
to treat cancer. Moreover, one should also take into consideration the possibility to manipulate the
exosome trafficking between these cells in order to inhibit tumor growth.
The main method to restore the immune system in cancer is immune checkpoint inhibition.
Immune checkpoint inhibitors have expanded treatment options for cancer patients with unfavorable
outcomes; however, an important limitation exists since only a small proportion of patients respond to
the therapy [157]. Therefore, alternative approaches need to be discovered to increase the proportion
of patients that could positively respond to immune checkpoint inhibitors. One solution would be the
inhibition of the molecular crosstalk between nerve and tumor cells. We briefly discuss below several
potential strategies that could accomplish this aspiration.
One of the simplest methods to block the pro-oncogenic signaling of nerves could be the use of
beta-blockers. In fact, numerous clinical trials are already assessing the efficacy of beta-blockers in
different cancers [36]. Alternatively, tumors could be decoupled from the pro-oncogenic signal of
nerves by performing surgical or chemical denervation (see Section 2.1).
The suppression of nerve recruitment within the TME and the inhibition of the reprograming
of nerves towards a pro-tumorigenic phenotype by cancer cells represents another possible strategy
to improve cancer outcomes. For instance, neurotrophic factors, like NGF, could be targeted using
monoclonal antibodies or siRNAs against them. Bapat et al. used anti-NGF siRNAs in pancreatic
cancer cell lines and observed that the migration of the cells towards DRGs was inhibited. Additionally,
rat pheochromocytoma cells (PC-12) cultured with conditioned media from pancreatic cancer cell lines
with NGF knock-down showed reduced neurite outgrowth [158].
Yet another option to block the pro-oncogenic signaling of nerves might be to stop exosome
production in cancer cells. We have showed that blocking the exosome secretion pathway by
double knock-out of RAB27A/RAB27B suppresses the ability of head and neck cancer cells to induce
the trans-differentiation of sensory nerves into adrenergic nerves, resulting in suppressed tumor
growth [95].
Moreover, the efficacy of combining immune checkpoint inhibitors with beta-blockers is supported
by epidemiologic data and pre-clinical experiments. By analyzing 195 patients with melanoma receiving
immunotherapy (either IL-2, anti-CTLA-4 and/or anti-PD1), it was remarked that the addition of
pan-beta-blockers was associated with a significantly better OS compared to patients receiving
immunotherapy plus beta1-blockers or no beta-blockers. By performing in vivo experiments, it was
confirmed that the addition of propranolol (non-selective beta-blocker) improved the survival of mice
receiving anti-PD1 or anti-PD1 and IL-2, but not of mice receiving IL-2 alone. In fact, beta-blockers
alone are enough to boost the efficacy of immune-based therapies in mice [159]. However, the authors
did not provide any additional results regarding the molecular mechanisms of action.
Thus, the crosstalks between nerves and cancer cells and between immune and cancer cells
seem to intersect and novel therapies need to be developed to simultaneously inhibit these
synergistic mechanisms. Compelling evidence suggest that exosomes play an important role in
these communication avenues and targeting exosomes or modulating their content could be an
innovative strategy to move this concept into clinical practice.
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